Artielle is a startup based in the United States.
Artielle develops novel first-in-class biologic therapies targeting neuroinflammatory diseases and advanced cancers, using a platform that modulates immune cell activity to treat conditions such as multiple sclerosis, substance use disorder, stroke, and advanced melanoma.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.